At the news
? BEARISHIMPACT 5/10 PRESS-RELEASE filed Sep 4, 2026 at 19:05 ET
Royalty Pharma announced that Novartis' Phase 3 HORIZON trial for pelacarsen failed to meet its primary endpoint in atherosclerotic cardiovascular disease. The company's $500 million Ionis funding agreement was structured with $350 million allocated to Spinraza royalties and only $150 million to pelacarsen, and Royalty Pharma expects to recoup its total investment and earn a modest positive return. The company reiterated its 2030 Portfolio Receipts target of $4.7 billion or more, limiting the financial damage from this clinical failure.
- Novartis' Phase 3 HORIZON trial for pelacarsen did not meet its primary endpoint in atherosclerotic cardiovascular disease.
- Royalty Pharma's $500 million Ionis funding agreement allocated $350 million to Spinraza royalties and $150 million to pelacarsen royalties.
- Royalty Pharma expects to recoup its total investment and earn a modest positive return despite the pelacarsen failure.
- Royalty Pharma reiterates its 2030 Portfolio Receipts target of $4.7 billion or more.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access